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Abstract 
Plasma levels of very long chain saturated fatty acids (VLCSFAs) are associated with metabolic 
syndrome (MetS). However, the associations may vary by different biological activities of individual 
VLCSFAs or population characteristics.We aimed to examine the associations of VLCSFAs and 
MetS risk in Chinese adults. Totally, 2008 Chinese aged 35 to 59 years were recruited and followed 
up from 2010 to 2012. Baseline MetS status and plasma fatty acids data were available for 1729 
individuals without serious diseases. Among 899 initially metabolically healthy individuals, we 
identified 212 incident MetS during the follow-up. Logistic regression analysis was used to estimate 
odds ratios (ORs) and 95% confidence intervals (CIs). Cross-sectionally, each VLCSFAs was 
inversely associated with MetS risk; comparing to the lowest quartile, the multivariate-adjusted ORs 
(95% CI) for the highest quartile were 0.18 (0.13, 0.25) for C20:0, 0.26 (0.18, 0.35) for C22:0, 0.19 
(0.13, 0.26) for C24:0 and 0.16 (0.11, 0.22) for total VLCSFAs (All P for trends <0.001). The 
associations remained significant after further adjusting for C16:0, C18:0, C18:3n3, C22:6n3, n-6 
polyunsaturated fatty acids and monounsaturated fatty acids, respectively. Based on follow-up data, 
C20:0 or C22:0 were also inversely associated with incident MetS risk. Among the 5 individual MetS 
components, higher levels of VLCSFAs were most strongly inversely associated with elevated 
triglyceride (≥1.7mmol/L). Plasma levels of VLCSFAs were significantly and inversely associated 
with MetS risk and individual MetS components, especially triglyceride. Further studies are 
warranted to confirm the findings and explore underlying mechanisms.  
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Introduction 
 Saturated fatty acids (SFAs) have been linked to the development of metabolic disorders, 
including diabetes(1), hyperlipidemia(2) and hypertension(3). The underlying mechanisms include 
activating nuclear factor-κB (NF-κB) to alter gene expression, serving as signal molecules, and 
modulating membrane fluidity(4, 5). The effect of straight chain SFAs on metabolic process depends 
on the carbon chain length. Excess dietary palmitic acid (C16:0) impairs insulin sensitivity and 
increases blood pressure and lipids(6, 7). In contrast, very long chain SFAs (VLCSFAs) with 20-24 
carbon atoms may play a favorable role in metabolic disorders. Several epidemiological studies 
reported that higher circulating levels of VLCSFAs were inversely associated with blood 
triglyceride(8), insulin resistance(9), incident diabetes(1, 8), arterial fibrillation(10), coronary heart 
disease(11), and cardioembolic stroke(12) and cardiovascular disease (CVD) mortality(13).  
 Circulating VLCSFAs are from minor dietary constituents and are also derived by endogenous 
synthesis from C16:0 or C18:0 as well as inter conversions among one another mediated by beta-
oxidation and elongation(14). VLCSFAs are found at significant quantities in a limited range of foods, 
including peanuts, lotus nuts, and rapeseed/canola oil(15). In vivo, VLCSFAs are major elements of 
ceramides and sphingomyelins, and the lower level of ceramides have been suggested to increase 
hepatocyte apoptosis and proliferation(16), obesity risk(17), and inflammatory response(17) among many 
other structural roles in, for instance, the brain and skin(18, 19). Further studies have reported that some 
functions of ceramides are chain-length dependent(20). For example, based on cell culture experiments, 
C24:0 promotes proliferation, whereas C16:0 often exhibits anti-proliferative and pro-apoptotic 
effects(20). Previous epidemiological studies show that VLCSFAs were reversely correlated with 
plasma phospholipid palmitic  acid(8,10). 
 To our knowledge, no studies to date have assessed the relation of VLCSFAs to metabolic 
syndrome (MetS) in a Chinese population. We aimed to explore the associations of plasma VLCSFAs 
with prevalence of MetS at baseline and risk of incident MetS of all initially metabolically healthy 
participants in a two-year follow-up study. Further, we additionally evaluated the associations 
between VLCSFAs with five MetS components. 
Methods 
Study Population 
The study population was from an investigation conducted by Chinese Center for Disease Control 
and Prevention from April 2010 to December 2012 in Shunyi district of Beijing. Eligible participants 
had to live in the area for more than one year, had no plan to move within one year, no serious diseases 
of heart, lung, liver and kidney and no pregnancy. A total of 2008 participants aged between 35 and 
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59 years were recruited in Shunyi. All participants were interviewed in-person to collect information 
on demographic characteristics, history of diseases, medical conditions, current cigarette smoking 
status (at least one cigarette a day), alcohol drinking status (at least once a week during the past year), 
physical activity status (at least once a week, excluding walking and riding), agricultural working 
(typical agricultural workers), health education (conducted by local Centers for Disease Control) and 
other lifestyles. Height, weight, blood pressure, and waist circumference were measured twice. 
Fasting venous blood was obtained for biochemical testing, including total cholesterol, high-density 
lipoprotein cholesterol, triglyceride, and plasma glucose. Plasma glucose was tested within 3 hours 
and plasma lipids on the day of sampling. All biochemical testing was performed with an automatic 
biochemical analyzer (Brand, manufacturer, city, province/state). Plasma was separated at 1500g/min 
centrifugation for 15min and stored at -80°C. The above information and bio-samples were collected 
a second time after two years.  
Among the 1915 participants with available baseline fatty acid data, we excluded 185 participants 
with coronary heart diseases, stroke, chronic respiratory diseases, and malignant tumor at baseline; 
one participant with no MetS information was also excluded. Finally, 1729 participants were included 
in the current analyses. Among them, 81% had the two-year follow-up data. 
The study protocol was approved by the Ethical Review Committee of the National Center for 
Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control 
and Prevention. All participants provided informed written consent. The trial was registered at 
chictr.org.cn as ChiCTR-EOC-17012759. 
Ascertainment of metabolic syndrome 
 MetS was defined according to the updated National Cholesterol Education Program Adult 
Treatment Panel III criteria for Asian Americans(21). Participants with any 3 of the 5 following items 
were identified as having MetS: 1) waist circumferences ≥ 90cm in men or ≥ 80cm in women, 2) 
triglycerides ≥ 1.7mmol/L, 3) HDL cholesterol ≤ 1.03mmol/L in men or ≤ 1.30mmol/L in women, 4) 
blood pressure ≥ 130/85mmHg or current use of antihypertensive medications and 5) fasting plasma 
glucose ≥ 5.6mmol/L or use of oral anti-diabetic agents or insulin. 
Plasma fatty acids measurement 
Gas chromatography/flame ionization detector (GC/FID) was used to measure plasma fatty 
acids profile(22, 23). Briefly, 100ul plasma with 1,2-dihenarachidoyl-sn-glycero-3-phosphocholine as 
internal standard was extracted in dichloromethane/methanol and the extracted lipids was reacted 
with methanol and sulfuric acid to yield fatty acid methyl ester (FAMEs). After methylation, 
FAMEs were extracted with n-hexane and re-dissolved in isooctane. Analysis was performed using 
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an Agilent 6890 GC/FID equipped with a Supelco SP-2560 capillary column (100m*0.25mm inside 
diameter *0.20um thickness). Data were expressed as weight percentage of total fatty acids. 
Samples were organized in batches of up to 20, which included two samples from a standard pool 
for quality control (QC). The CVs of QC were 10.8% for C20:0 (arachidic acid), 12.4% for C22:0 
(behenic acid) and 14.6% for C24:0 (lignoceric acid). 
Statistical analysis 
Wilcoxon rank sum test for continuous variables and the chi-square test for categorical variables 
were used to examine differences of basic characteristics between groups with MetS and without 
MetS. Spearman correlation was used to evaluate correlations of VLCSFAs and other plasma fatty 
acids. Logistic regression analysis was applied to examine the associations of VLCSFAs and risk of 
MetS. VLCSFAs were classified into four groups based on the quartiles of VLCSFAs in participants 
without metabolic syndrome at baseline. Several models were fitted to examine the association of 
each VLCSFA and risk of MetS: 1) model adjusted for age, sex, and agricultural work (main model); 
2) model adjusted for age, sex, agricultural work, education, smoking, alcohol drinking and physical 
activity (fully adjusted model); 3) models additionally adjusted for the potential mediators based on 
fully adjusted model, including C16:0, C18:0, C18:3n3, C22:6n3, n-6 polyunsaturated fatty acids (n-
6 PUFAs) and monounsaturated fatty acids (MUFAs) (exploration models). These selected fatty acids 
were significantly correlated with VLCSFAs with the spearman coefficients more than 0.25. As the 
fully adjusted models didn't change the results, main model was used in the following analyses. The 
associations of VLCSFAs and risk of incident metabolic syndrome during two year follow-up were 
conducted only in participants without MetS at baseline. Non-linear odds ratio of MetS was estimated 
by applying a restricted cubic spline regression model with 3 knots at the 5th, 50th and 95th 
percentiles(24).Multinomial logistic regression was used to estimate the associations of VLCSFAs and 
risk of metabolic syndrome according to the number of metabolic syndrome components at baseline. 
As the sample size in each group was limited, the VLCSFAs levels were classified into high or low 
group based on the median of VLCSFAs in subjects without metabolic syndrome. Low VLCSFAs 
levels group were assigned as the reference. When the associations between VLCSFAs and individual 
components of MetS were evaluated, each of the other four components was adjusted in the models 
separately. To explore modification effects of some a priori risk factors on the association between 
VLCSFAs and MetS risk, stratified analyses were conducted by age, sex, physical activity, 
agricultural working, smoking status and current alcohol drinking. Continuous variables were 
classified into high versus low levels based on the median levels in controls. The ORs were expressed 
as the risk of metabolic syndrome for one SD increase of VLCSFAs. Likelihood ratio tests were 
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conducted to examine interactions. All analyses were conducted with R software and SAS 9.3 
software. All P-values were two-sided. 
Results 
 A total of 1,729 participants were included in this study; 565(32.7%) of these were identified as 
MetS at baseline. Baseline characteristics of participants with or without MetS were presented in 
Table 1. The two groups were similar in sex, smoking status, alcohol drinking and physical activity. 
Compared to participants without MetS, MetS participants were older and did less agricultural work. 
The MetS group had lower level of plasma C18:0, C20:0, C22:0, C24:0, C22:6n3, C18:2n6, C20:4n6, 
and n-6 PUFA, but had higher C16:0, MUFA, C18:3n3, C20:5n3, and n-3 PUFAs. Women and 
individuals without diabetes had higher levels VLCSFAs (Supplemental Table S1a, Supplemental 
Table S1b). In addition, higher VLCSFAs were associated with lower BMI, lower triglycerides, and 
higher HDL. Participants with higher levels of C20:0 or C22:0 tended to be non-smoker and non-
alcohol drinker, do more agricultural work, have no hypertension, and have lower WC and cholesterol 
(Supplemental Table S1a). Furthermore, older ages were inversely related to higher C20:0, but 
directly to higher C24:0 (Supplemental Table S1a, Supplemental Table S1b). Participants with higher 
C24:0 were more likely to have hypertension (Supplemental Table S1b). 
 All the three VLCSFAs were significantly correlated with each another (rs=0.75, 0.23, 0.21 for 
C20:0 with C22:0, C24:0, and C22:0 with C24:0, Supplemental Table S2). In the fully adjusted model, 
compared to the lowest quartile, the highest level of VLCSFAs was associated with increased risk of 
MetS; the multivariate-adjusted ORs (95% CI) were 0.18 (0.13, 0.25) for C20:0, 0.26 (0.18, 0.35) for 
C22:0, 0.19 (0.13, 0.26) for C24:0, and 0.16 (0.11, 0.22) for total VLCSFAs (Table 2). Odds ratios of 
MetS were non-linear in C20:0, C22:0, C24:0, and total VLCSFAs (Figure 1, Pnon-linearity<0.0001 for 
C20:0 and total VLCSFAs, Pnon-linearity=0.002 for C22:0, Pnon-linearity=0.021 for C24:0). The VLCSFAs 
were significantly correlated with C16:0, C18:0, MUFAs, C18:3n3, C22:6n3 and n-6PUFAs with 
absolute rs more than 0.25 (Supplemental Table S2). Separately adjusted for these fatty acids did not 
affect the associations between VLCSFAs and MetS risk (Supplemental Table S3). In addition, the 
VLCSFAs levels were inversely associated with the number of MetS components (all the 
Ptrend<0.0001, Supplemental Table S4). In the multinomial logistic regression analysis, the 
associations of VLCSFAs and MetS risk were stronger with the increase of the number of MetS 
components (Table 3). 
 Among 899 subjects without MetS at baseline, we identified 212 incident cases of MetS during 
the two-year follow up. The level of C20:0, C22:0, and total VLCSFAs were significantly associated 
with decreased incident MetS risk; comparing to the lowest quartile, the multivariate-adjusted ORs 
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(95% CI) for the highest quartile were 0.21 (0.12, 0.35) for C20:0, 0.20 (0.11, 0.34) for C22:0, 0.75 
(0.44, 1.26) for C24:0, 0.28 (0.17, 0.46) for total VLCSFAs (Table 4).  
 VLCSFA levels and single MetS component associations were analyzed. Among the five MetS 
components, the associations were strongest for VLCSFAs and elevated triglyceride (Q4 vs Q1: ORs 
(95% CI) were 0.11 (0.07, 0.17) for C20:0, 0.10 (0.06, 0.16) for C22:0, 0.07 (0.04, 0.12) for C24:0, 
0.04 (0.02, 0.07) for total VLCSFAs, Ptrend<0.0001, Figure 2, Supplemental Table S5). 
 We also explored effect modification on the associations of VLCSFAs and MetS risk by several 
a priori risk factors, including age, sex, smoking status (yes and no), current alcohol drinking (yes 
and no), physical activity, and agricultural working (Figure 3). The inverse associations between 
C20:0 and MetS risk were stronger in women than in men (OR=0.37 (95% CI: 0.31-0.44) for women 
and OR=0.57 (95% CI: 0.46-0.69) for men; P for interaction=0.002) and in non-alcohol drinkers than 
in current alcohol drinkers (OR=0.38 (95% CI: 0.32-0.45) for non-alcohol drinkers and OR=0.61 (95% 
CI: 0.49-0.75) for current alcohol drinkers; P for interaction=0.0008) (Figure 3). 
Discussion 
 In a population of 1729 Chinese adults, we observed that plasma VLCSFAs levels were 
significantly and inversely associated with prevalence and incidence of MetS. Further adjustment for 
each of C16:0, C18:0, C18:3n3, C22:6n3, n-6 polyunsaturated fatty acids (n-6 PUFAs), or 
monounsaturated fatty acids (MUFAs) did not negate the associations. The associations of VLCSFAs 
and MetS risk became stronger with the increase of the number of MetS components. Among the five 
individual MetS components, higher plasma VLCSFAs were strongly associated with plasma 
triglycerides. 
 Our observations are generally in line with several previous studies that have reported the 
relationship between blood VLCSFAs and various metabolic conditions in other populations(1, 8, 10-13, 
25). Three prospective studies published recently showed that higher levels of three VLCSFAs (C20:0, 
C22:0, and C24:0) were associated with lower risk of incident diabetes(1, 8, 27). A study with 3179 
participants from the Cardiovascular Health Study (CHS) reported that higher plasma phospholipid 
VLCSFAs were cross-sectionally associated with lower blood triglyceride and waist circumference 
(WC)(8). In the Nurses' Health Study (NHS) and Health Professionals Follow-Up Study (HPFS), 
plasma VLCSFAs were positively correlated with high density lipoprotein (HDL)(11). Diabetes, WC, 
circulating triglycerides and HDL are components of MetS. Consistently, we found inverse 
associations between plasma VLCSFAs and MetS risk; triglycerides showed the strongest 
associations with VLCSFAs. In addition, we found significant inverse associations of C20:0 and 
C22:0 with WC, and direct associations of C24:0 with HDL. However, we observed that C22:0 and 
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C24:0 were directly associated with fasting blood glucose, which was different from the results of 
above studies. If the covariate of triglycerides was excluded from the analyses model in our study, 
the associations of C22:0 and C24:0 with fasting blood glucose were reversed. In the CHS study, 
VLCSFAs were associated with lower risk of diabetes, but if blood triglyceride was adjusted in the 
model, the associations were not significant(8). This suggested that the associations of VLCSFAs with 
blood glucose might be mediated by lower triglycerides. Mechanistic studies are needed to confirm 
these results. Other recently published studies reported inverse associations of circulating levels of 
VLCSFAs with atrial fibrillation(10), cardioembolic stroke(12), coronary heart diseases (CHDs)(11), and 
total mortality(13). MetS was a major intermediate risk factor of these diseases and may explain these 
associations(26-28).  
 The biological functions of VLCSFAs in vivo remain unclear. VLCSFAs are major components 
of ceramides and sphingomyelins which are key intermediates linking saturated fats and 
inflammatory cytokines to regulate cell function. MetS is associated with insulin resistance. C16-
ceramide has been suggested to induce β-cell apoptosis, modulate insulin signaling and reduce insulin 
synthesis, which causes insulin resistance(29). In contrast, little is known about the role of VLCSFAs-
ceramide in insulin resistance. C16-ceramide may damage the heart, pancreas, and vasculature, and 
thus may induce diabetes, cardiovascular diseases, and atherosclerosis(30). However, very long chain 
ceramides are likely to have opposite biological activities. For example, in cell culture and animal 
studies, C16 ceramide promoted hepatocellular hyperplasia whereas C24 ceramide did not(16). In 
Langmuir–Blodgett monolayer experiments, C16 ceramide mixed well with cholesterol whereas C24 
ceramide did not(31), suggesting that lipid raft functionality with higher level C24 ceramides may be 
impaired and apoptosis reduced subsequently(32). In addition, very-long-chain acyl-CoA synthetase 
may be up-regulated by PPARδ and evidence showed that PPARδ played a role in fat metabolism to 
prevent obesity(33). 
 The sources of circulating VLCSFAs include both exogenous diet and endogenous synthesis(14). 
The VLCSFAs are found in limited foods, including peanuts, lotus nuts, and rapeseed/canola oil(15). 
Several studies have shown that peanut intake increases blood C22:0 and C24:0(8). Interestingly, 
peanut butter consumption was significantly associated with a more favorable plasma lipid profile, 
including lower LDL cholesterol, and total cholesterol in the Nurses’ Health Study(34). VLCSFAs can 
be synthesized from C18:0 by elongases, especially the ELOVL1, which selectively elongates SFAs 
with more than 18 carbons(14). Indeed our data show that the fatty acids related to each other by a 
single round of elongation were highly correlated, suggesting that higher dietary intake resulted in 
higher levels of the elongation product: 18:020:0 and 20:022:0 (the spearman coefficients were 
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0.48 for C18:0 and C20:0, and 0.75 for C20:0 and C22:0). The ELOVL1 gene coding for the first 
committed step in elongation, is regulated in concert with the ceramide synthase CERS2, a key 
enzyme for C24 sphingolipid synthesis(35). This regulation may ensure that the production of C24-
CoA by elongation is coordinated with its utilization. How the dietary intake and endogenous 
metabolism contribute to circulating levels of VLCSFAs and subsequently affect the metabolic 
disorders requires further study. 
 We also explored the modifying effects by several a priori factors on the relation of VLCSFAs 
to MetS risk. We found a stronger association between C20:0 and MetS risk in subjects without 
alcohol drinking than those with current alcohol drinking. This phenomenon was consistent with the 
finding in the CHS study and our study that C20:0 was inversely correlated with the amount of alcohol 
drinks and current alcohol drinking status (Yes/No)(8). Heavy alcohol drinking is a risk factor for 
MetS(36), and may neutralize the beneficial effects of VLCSFAs on MetS. We also observed moderate 
interaction effects of sex on the association of C20:0 with MetS. In the CHS study and our study, 
women tended to have higher C20:0(8), which may explain our findings that the association of C20:0 
and MetS risk was stronger in women than in men. 
Our study is the first study to explore the associations of plasma VLCSFAs and MetS risk in 
Chinese population. Our study has some limitations. First, the study design was initially cross-
sectional, but we confirmed the cross-sectional results among baseline non-MetS subjects with two-
year follow-up data. Second, the half-life of plasma fatty acids was short and it may not reflect long-
term dietary pattern. The fatty acids of erythrocyte or fat adipose tissue were needed to confirm the 
associations of VLCSFAs with MetS risk. Third, we analyzed statistically plasma fatty acids in units 
of weight% as is reported in most studies(8,11), which is most useful in assessing whether fatty acid 
imbalance  is related to metabolic status. Specific fatty acid concentrations (e.g. mg/ml plasma) is 
more appropriate to assess whether the mass of a specific circulating fatty acid is outside of a range 
needed to support the metabolism under study. In addition, the fatty acids in various lipid classes (for 
instance, triglyceride, sphingomyelins) were not measured and would provide more specific insight 
into VLCSFAs’ biological function. Fourth, no information on the lipid-lowering medication use was 
available. However, the hyperlipidemia awareness rates (8.3%), treatment rates (7.0%), and detection 
rates (26.2%) were very low in China, especially in rural area(37), which suggests a possible mild 
lipid-lowering medication influence. We also adjusted for other potential confounders including 
lifestyle factors in the statistics model, but residual confounding by non-available or unknown factors 
is also possible, such as menopausal status of women or dietary VLCSFAs.  
 In summary, we confirmed that higher levels of plasma VLCSFAs are significantly associated 
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with lower risk of MetS in Chinese adults. The association of VLCSFAs with blood triglycerides was 
stronger than other four MetS components. Further studies are warranted to explore the underlying 
mechanisms. 
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Table 1.Basic characteristics of subjects with and without metabolic syndrome at baseline 
Characteristics* With MetS 
(n=565) 
Without MetS 
(n=1164) 
P value† 
Age 50.5 (5.95)   48.5 (6.28) <0.0001 
Sex    0.52 
Male 185 (33%) 401(34%)  
Female 380 (67%) 763 (66%)  
Education    0.43 
illiteracy 18 (3%) 25 (2%)  
Primary School 73 (13%) 126 (11%)  
Middle School 353 (62%) 746 (64%)  
High School 115 (20%) 251 (22%)  
College 6 (1%) 16 (1%)  
Health education 262(46%) 598(51%)  0.06 
Current smoking status 116 (21%) 265 (23%)  0.32 
Current alcohol 
drinking 
146 (26%) 304 (26%)  0.95 
Agricultural work 243 (43%) 612 (53%) 0.0002 
Physical activity 72 (13%) 150 (13%)  0.99 
BMI(kg/m2) 28.5 (3.06)  25.2 (3.36) < 0.0001 
WC(cm) 92.9 (8.54) 82.4 (9.42) < 0.0001 
Obesity 308 (55%) 218 (19%) < 0.0001 
Hypertension 398 (70%) 415 (36%) < 0.0001 
Diabetes 112 (20%) 33 (3%) < 0.0001 
TG 2.33 (1.81) 1.07 (1.06) < 0.0001 
TC 5.44 (1.05) 5.17 (0.88) < 0.0001 
HDL-c 1.23 (0.28) 1.55 (0.31) < 0.0001 
C16:0 21.1 (1.81) 19.8 (1.45) < 0.0001 
C18:0 7.95 (0.84) 8.52 (0.81) < 0.0001 
C20:0 0.18 (0.04)  0.21 (0.04) < 0.0001 
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C22:0 0.63 (0.19) 0.73 (0.20) < 0.0001 
C24:0 0.49 (0.19) 0.60 (0.21) < 0.0001 
Total VLCSFAs 1.30 (0.32) 1.53 (0.32) < 0.0001 
MUFAs‡ 20.6 (3.11) 18.0 (2.46) < 0.0001 
C18:3n3 0.93 (0.34) 0.74 (0.26) < 0.0001 
C20:5n3 0.48 (0.20) 0.48 (0.28) < 0.0001 
C22:6n3c 1.87 (0.57) 1.95 (0.60)  0.002 
n3PUFAs§ 3.77 (0.73) 3.65 (0.82) < 0.0001 
C18:2n6 33.9 (3.80) 36.1 (3.80) < 0.0001 
C20:4n6 7.32 (1.79) 8.55 (1.73) < 0.0001 
n6PUFAs|| 44.2 (3.99) 47.6 (3.06) < 0.0001 
*Continuous variables were expressed as mean (SD) and categorical variables were expressed as 
frequency(percentage among cases or controls). 
†P-value were calculated from Wilcoxon rank sum test for continuous variables and χ2-test for 
categorical variables 
‡MUFAs: monounsaturated fatty acids, which includes C14:1n5, C16:1n7, C16:1n9, C18:1n7, 
C18:1n9, C20:1n9, C22:1n9 and C24:1n9 in this study 
§n-3PUFAs: n-3 polyunsaturated fatty acids, which includes C18:3n3, C20:3n3, C20:5n3, C22:3n3, 
C22:5n3 and C22:6n3 
||n-6PUFAs: n-6 polyunsaturated fatty acids, which includes C18:2n6, C18:3n6, C20:2n6, C20:3n6, 
C20:4n6, C22:2n6, C22:4n6 and C22:5n6 in this study  
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Table 2. The associations of VLCSFAs and prevalence of metabolic syndrome at baseline 
 Quartile 1  Quartile 2 Quartile 3      Quartile 4    P trend 
C20:0      
N MetS/non-MetS 326/291 101/291 80/291 58/291  
Model 1 1 0.30 (0.23, 0.40) 0.25 (0.18, 0.33) 0.18 (0.13, 0.25) <0.0001 
Model 2 1 0.30 (0.23, 0.40) 0.25 (0.18, 0.33) 0.18 (0.13, 0.25) <0.0001 
C22:0      
N MetS/non-MetS 248/291 153/291 98/291 66/291  
Model 1 1 0.58 (0.44, 0.75) 0.38 (0.28, 0.50) 0.26 (0.18, 0.35) <0.0001 
Model 2 1 0.58 (0.44, 0.75) 0.38 (0.28, 0.50) 0.26 (0.18, 0.35) <0.0001 
C24:0      
N MetS/non-MetS 260/291 160/291 90/291 55/291  
Model 1 1 0.55 (0.42, 0.72) 0.30 (0.22, 0.40) 0.18 (0.13, 0.26) <0.0001 
Model 2 1 0.55 (0.42, 0.71) 0.30 (0.22, 0.40) 0.19 (0.13, 0.26) <0.0001 
Total VLCSFAs      
N MetS/non-MetS 312/291 130/291 70/291 53/291  
Model 1 1 0.38 (0.29, 0.50) 0.21 (0.15, 0.29) 0.16 (0.11, 0.22) <0.0001 
Model 2 1 0.38 (0.29, 0.50) 0.21 (0.15, 0.29) 0.16 (0.11, 0.22) <0.0001 
Logistic regression was used to estimate the ORs and CIs. VLCSFAs were classified into four group 
based on the quartiles of VLCSFAs in subjects without metabolic syndrome: 0.18, 0.20 and 0.23 for 
C20:0; 0.59, 0.70 and 0.84 for C22:0; 0.46, 0.61 and 0.73 for C24:0; 1.32, 1.51 and 1.72 for total 
VLCSFAs.  
Model 1: adjusted for sex, age, agricultural work. 
Model 2: additionally adjusted for education, smoking, alcohol drinking, physical activity.  
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Table 3. The associations of VLCSFAs and risk of metabolic syndrome according to the number 
of metabolic syndrome components at baseline 
 MS=0 MS=3 MS=4 MS=5 
20:0     
Nhigh/low 582/582 80/251 44/138 14/38 
ORs 1 0.33 (0.25, 0.44) 0.33 (0.23, 0.47) 0.39 (0.21, 0.72) 
22:0     
Nhigh/low 582/ 582 81/ 250 69/ 113 14/ 38 
ORs 1 0.32 (0.24, 0.43) 0.61 (0.44, 0.84) 0.36(0.19, 0.67) 
24:0     
Nhigh/low 582/ 582 134/ 197 8/ 174 3/49 
ORs 1 0.63 (0.49, 0.81) 0.04 (0.02, 0.09) 0.05 (0.02, 0.18) 
Total VLCSFAs     
Nhigh/low 582/ 582 97/234 24/158 2/50 
ORs 1 0.40 (0.31, 0.53) 0.15 (0.09, 0.23) 0.04 (0.01, 0.16) 
Multinomial logistic regression was used to estimate the ORs and CIs. All the ORs was adjusted for 
sex, age, and agricultural work. As the sample size in each case group was limited, VLCSFAs were 
classified into high/low group based on the median of VLCSFAs in subjects without metabolic 
syndrome. Low group was the reference. ORs, odds ratios. 
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Table 4. The associations of VLCSFAs and risk of incident metabolic syndrome after two years 
 Quartile 1  Quartile 2 Quartile 3  Quartile 4 P trend 
C20:0      
NMetS/non-MetS 89 /172 62/171 43/172 18/172  
 1 0.67 (0.45, 1.00) 0.47 (0.30, 0.72) 0.21 (0.12, 0.35) <0.001 
C22:0      
NMetS/non-MetS 89 /172 65/171 38/172 20 /172  
 1 0.64 (0.43, 0.95) 0.40 (0.25, 0.62) 0.20 (0.11, 0.34) <0.001 
C24:0      
NMetS/non-MetS 38 /172 87/171 52/172 35/172  
 1 1.94 (1.25, 3.06) 1.15 (0.71, 1.87) 0.75 (0.44, 1.26) 0.11 
Total VLCSFAs      
NMetS/non-MetS 80 /172 62 /171 44 /172 26/172  
 1 0.71 (0.47,1.07) 0.51(0.33, 0.78) 0.28 (0.17, 0.46) <0.001 
Only subjects without MetS at baseline were included in the analysis. VLCSFAs were classified into 
four group based on the quartiles of VLCSFA in subjects without MetS: 0.18, 0.21 and 0.23 for C20:0; 
0.60, 0.73 and 0.86 for C22:0; 0.46, 0.63 and 0.75 for C24:0; 1.32, 1.51 and1.72 for total VLCSFAs. 
Models were adjusted for sex, age, agricultural work 
 
Figure Legend 
Figure 1 Odds ratios of MetS by VLCSFAs levels at baseline. Lines represent odds ratios (95% CI) 
based on restricted cubic splines for VLCSFAs levels with knots at the 5th, 50th and 95th percentiles. 
Odds ratios were estimated using a logistic regression model after adjustment for age, sex, agricultural 
work; Bars represent the numbers of participants. (A) C20:0 (Pnon-linearity < 0.001), (B) C22:0 (Pnon-
linearity = 0.002), (C) C24:0 (Pnon-linearity = 0.021), (D) total VLCSFAs (Pnon-linearity < 0.0001) 
Figure 2 The associations of VLCSFAs and risk of metabolic syndrome components at baseline. 
Logistic regression was used to estimate the ORs and CIs. All the ORs was adjusted for age, sex, and 
agricultural work. The five components were adjusted in the models, except for itself.The five 
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components were classified into high/low group according to the cut-off in metabolic syndrome 
definition. BP: blood pressure, FBG: fasting blood glucose, HDL: high density lipoprotein, TG: 
triglyceride, WC: waist circumference 
Figure 3 Stratified analysis of the associations of VLCSFAs and risk of metabolic syndrome at 
baseline. All the ORs were adjusted for age, sex, and agricultural work. The ORs meant the risk of 
metabolic syndrome for one SD increase of VLCSFAs. 
Supplemental Table 1a. Characteristics of participants according to plasma C20:0 and C22:0 
Characteristics* C20:0†   C22:0†  
 Q1 Q2 Q3 Q4 Ptrend  Q1 Q2 Q3 Q4 Ptrend 
Age 50(6) 50(6) 49(6) 48 (6) <0.0001  49 (6) 49 (6) 49(6) 49(6) 0.14 
Sex     <0.0001      <0.0001 
Male 189(44%) 144(33%) 131(30%) 122(28%)   202(47%) 138(32%) 119(27%) 128(30%)  
Female 243(56%) 288(67%) 302 (70%) 311(72%)   230 (53%) 294 (68%) 314 (73%) 305(70%)  
Education     0.32      0.15 
illiteracy 10(2%) 9(2%) 11(3%) 13 (3%)   11(3%) 10(2%) 9(2%) 13(3%)  
Primary School 52(12%) 54(12% ) 56 (13%) 37(9%)   50 (12%) 60(14%) 46(11%) 43(10%)  
Middle School 276(64%) 269(62% ) 277(64%) 78(64%)   280(65%) 275(64%) 272(63%) 273(63%)  
High School 86(20%) 97(22% ) 85 (20%) 98(23%)   83(19%) 84(19%) 99(23%) 100(23%)  
College 8(2%) 3(1% 4 (1%) 7(2%)   8(2%) 3(1%) 7 (2% ) 4(1%)  
Current smoking status 123(28%) 86(20%) 84(19%) 88(20%) 0.01  141(33%) 76(18%) 74(17%) 91(21%) 0.0002 
Current alcohol drinking 133(31%) 107(25%) 106(24%) 104(24%) 0.03  146(34%) 98(23% ) 103(24%) 104(24%) 0.004 
Agricultural work 190(44%) 211(49%) 220(50%) 234(54%) 0.003  207(48%) 217(50%) 206(48%) 226(52%) 0.3 
Physical activity 52(12%) 54(12%) 61(14%) 55(13%) 0.67  53(12%) 72(17%) 52(12%) 46(11%) 0.17 
BMI(kg/m2) 27.1(3.3) 26.7(3.8) 26.0(3.5) 25.4(3.7) <0.0001  26.3(3.6) 26.5(3.5) 26.4(3.6) 25.4(3.7) <0.0001 
WC(cm) 88.9(9.7) 87.0(10.2) 84.9(10.1) 82.7(10.6) <0.0001  88.3(9.6) 86.6(10.1) 85.8(10.3) 82.8(10.8) <0.0001 
Obesity 169(39%) 147(34%) 116(27%) 95 (22%) <0.0001  164 (38%) 141 (33%) 133 (31%) 88 (20%) <0.0001 
Hypertension 245(57%) 222(51%) 202(47%) 145(33%) <0.0001  250 (58%) 212 ( 49%) 200 (46%) 151 (35%) <0.0001 
Diabetes 57(13%) 40(9%) 28(6% ) 20(5%) <0.0001  43(10%) 44 (10% ) 34(8%) 24(6%) 0.01 
TG 2.27(1.91) 1.43(0.98) 1.19(0.98) 1.04(1.5) <0.0001  2.39(2.41) 1.4 0(0.79) 1.2(0.84) 0.94(0.61) <0.0001 
TC 5.48(1.02) 5.34(0.90) 5.17(0.87) 5.03(0.9 ) <0.0001  5.41(1.06) 5.23(0.92) 5.26(0.90) 5.12(0.88) <0.0001 
HDL-c 1.34(0.31) 1.44(0.32) 1.50(0.34) 1.53(0.35) <0.0001  1.35(0.34 ) 1.42 (0.32) 1.48(0.32) 1.54(0.34) <0.0001 
*Continuous variables were expressed as mean (SD) and categorical variables were expressed as frequency (percentage of case ). 
†VLCSFAs were classified into four group based on the quartiles of VLCSFAs in all subjects: 0.17, 0.20 and 0.22 for C20:0; 0.57, 0.68 and 0.81 for C22:0. 
 
Supplemental Table 1b. Characteristics of participants according to plasma C24:0 and total VLCSFAs 
Characteristics*   C24:0†     Total VLCSFAs†  
 Q1 Q2 Q3 Q4 Ptrend  Q1 Q2 Q3 Q4 Ptrend 
Age 48 (7) 49 (6) 50(6) 50 (6) <0.0001  49(6) 49(6) 49(6) 49(6) 0.24 
Sex     0.04      0.005 
Male 140(32%) 141(33%) 131(30%) 174(40%)   181(42% ) 132(31%) 136(31%) 138(32%)  
Female 292(68%) 291(67%) 302(70%) 259(60%)   251(58% ) 300(69%) 297(69%) 295(68%)  
Education     0.89      0.75 
illiteracy 9 (2%)  12 (3%) 12 (3%) 10 (2%)     6 (1%) 16 (4% )  9 (2%)  12 (3%)  
Primary School 44 (10%) 61 (14%) 49 (11%) 45 (11%)   47 (11%) 59 (14%) 48 (11%) 45 (10%)  
Middle School 276(64%) 273 (63%) 268(62%) 282(65%)   283 (66%) 267 (62%) 271 (63%) 279 (64%)  
High School 99 (23%) 81 (19%) 97 (22%) 90 (21%)   90 (21%) 86 (20%) 98 (23%) 92 (21% )  
College 4 (1%) 5 (1%) 7 (2%) 6 (1%)   6 (1%) 4 (1%) 7 (2%) 5 (1%)  
Current smoking status 100(23%) 87 (20%) 81(19% ) 113(26% ) 0.47  116(27% ) 87 (20%) 84 (19% ) 95(22% ) 0.01 
Current alcohol drinking 112(26%) 103(24%) 98(23%) 137(32% ) 0.11  131(30% )  98(23%) 112(26% ) 110(25% ) 0.21 
Agricultural work 205(47%) 207(48%) 212(49% ) 232(54% ) 0.08  204(47%) 208(48%) 208(48%) 236(55%) 0.04 
Physical activity 53(12% ) 67.0(16%) 59 (14%) 43 (10%) 0.28  53 (12% ) 60 (14%) 64 (15%) 45 (10%) 0.44 
BMI(kg/m2) 26.4(3.8) 26.8 (3.8) 26.2 (3.5)    25.8 (3.2) 0.01  27.3(3.4) 26.3(3.8)  25.9(3.7) 25.6(3.3) <0.0001 
WC(cm) 85.9(11.6) 87.0(10.5) 85.7(10.1) 84.8(9.2 ) 0.07  89.2( 9.9 ) 85.8(10.5) 84.8(10.7) 83.7(9.6) <0.0001 
Obesity 146(34%) 154 (36%) 132 (30%) 94 (22%) <0.0001  185 (43%) 137 (32%) 116 (27%) 88 (20%) <0.0001 
Hypertension 168(39%) 204 (47%) 224(52%) 218 (50%) 0.0002  237 (55%) 193 (45%) 187 (43%) 197 (45%) 0.01 
Diabetes 51 (12%) 38.0(9%) 34 (8%) 22 (5%) 0.0004  54 (12%)  39 (9%) 29 (7%) 23 (5%) <0.0001 
TG 2.11(2.46) 1.63 (0.95) 1.22(0.65)  0.97(0.78) <0.0001  2.49 ( 2.39) 1.44(0.83)  1.10(0.5) 0.9 (0.75) <0.0001 
TC 5.23(1.06 ) 5.30(0.88) 5.3(0.90)    5.19(0.95) 0.64  5.35( 1.06 ) 5.28(0.89) 5.21 (0.89) 5.17(0.93) 0.003 
HDL-c 1.35(0.36) 1.42(0.32) 1.50(0.32) 1.53(0.33) <0.0001  1.3 ( 0.31) 1.44(0.32) 1.50 (0.31) 1.56(0.35) <0.0001 
*Continuous variables were expressed as mean (SD) and categorical variables were expressed as frequency (percentage of case ). 
†VLCSFAs were classified into four group based on the quartiles of VLCSFAs in all subjects included in analysis: 0.40, 0.57 and 0.70 for C24:0; 1.23, 1.43 and 
1.65 for total VLCSFAs. 
 
Supplemental Table 2. Spearman correlation coefficients for plasma fatty acids 
  C20:0 C22:0 C24:0 total 
VLCSFAs 
C16:0 C18:0 MUFAs‡ C18:3n3 C20:5n3 C22:6n3 n3PUFA
s§ 
C18:2n6 C20:4n6 n6PUFAs|| 
Percentage 
of total 
fatty acids † 
0.20 
(0.17, 
0.22) 
0.68 
(0.57, 
0.81) 
0.57 
(0.40, 
0.70) 
1.43 
(1.23, 1.65) 
20.1 
(19.0, 
21.2) 
8.31 
(7.78, 
8.84) 
18.5 
(16.8, 
20.3) 
0.76 
(0.59, 
0.96) 
0.42 
(0.29, 
0.63) 
1.82 
(1.55, 
2.16) 
3.59 
(3.17, 
4.13) 
35.6 
(33.1, 
37.9) 
8.21 
(6.86, 
9.44) 
46.9 
(44.4, 
49.0 ) 
C20:0 1.00              
C22:0 0.75** 1.00             
C24:0 0.23** 0.21** 1.00            
total VLCSFAs 0.69** 0.79** 0.72** 1.00            
C16:0 -0.34** -0.34** -0.13** -0.31**  1.00          
C18:0 0.48** 0.36** 0.13** 0.35**  -0.23** 1.00          
MUFAs -0.48**  -0.49** -0.22** -0.47**  0.54** -0.51**  1.00         
C18:3n3 -0.37** -0.42** -0.27** -0.45**  0.03 -0.25**  0.10**  1.00        
C20:5n3 0.12** 0.26** -0.50** -0.11**  0.04 0.16**  -0.15**  0.05*  1.00       
C22:6n3 0.23** 0.27** -0.15** 0.10**  -0.12**  0.19**  -0.20**  -0.11** 0.41**  1.00      
n3PUFAs 0.05* 0.10** -0.42** -0.16**  -0.05* 0.10**  -0.16**  0.34** 0.71**  0.76** 1.00     
C18:2n6 0.23**  0.25**  0.12** 0.22**  -0.68** 0.06*  -0.62**  0.11** -0.21**  -0.15** -0.17** 1.00    
C20:4n6 0.28**  0.27**  0.27**  0.36**  -0.29**  0.31**  -0.42**  -0.39** 0.20**  0.29** 0.13** -0.13**  1.00   
n6PUFAs 0.35**  0.37**  0.24**  0.39**  -0.81**  0.22**  -0.83**  -0.07*  -0.09**  -0..004 -0.08**  0.85**  0.35**  1.00  
†present as median(interquartile) 
‡MUFAs: monounsaturated fatty acids, which includes C14:1n5, C16:1n7, C16:1n9, C18:1n7, C18:1n9, C20:1n9, C22:1n9 and C24:1n9 in this study 
§n3PUFAs: n-3 polyunsaturated fatty acids, which includes C18:3n3, C20:3n3, C20:5n3, C22:3n3, C22:5n3 and C22:6n3 
|| n6PUFAs: n-6 polyunsaturated fatty acids, which includes C18:2n6, C18:3n6, C20:2n6, C20:3n6, C20:4n6, C22:2n6, C22:4n6 and C22:5n6 in this study 
*P-value < 0.05; **P-value < 0.001 
  
Supplemental Table 3. The associations of VLCSFAs and prevalence of metabolic syndrome at baseline 
 Q1  Q2 Q3  Q4    P trend 
C20:0      
N MetS/non-MetS 326/291 101/291 80/291 58/291  
Model 1 1 0.30 (0.23, 0.40) 0.25 (0.18, 0.33) 0.18 (0.13, 0.25) <0.001 
Model 2 1 0.43 (0.32, 0.58) 0.40 (0.29, 0.54) 0.28 (0.20, 0.40) <0.001 
Model 3 1 0.39 (0.29, 0.52) 0.35 (0.26, 0.48) 0.26 (0.18, 0.37) <0.001 
Model 4 1 0.45 (0.33, 0.61) 0.44 (0.32, 0.61) 0.38 (0.26, 0.54) <0.001 
Model 5 1 0.41 (0.30, 0.55) 0.36 (0.26, 0.49) 0.32 (0.23, 0.46) <0.001 
Model 6 1 0.37 (0.28, 0.49) 0.33 (0.24, 0.45) 0.28 (0.19, 0.39) <0.001 
Model 7 1 0.30 (0.23, 0.40) 0.25 (0.18, 0.33) 0.18 (0.13, 0.25) <0.001 
C22:0      
N MetS/non-MetS 248/291 153/291 98/291 66/291  
Model 1 1 0.58 (0.44, 0.75) 0.38 (0.28, 0.50) 0.26 (0.18, 0.35) <0.001 
Model 2 1 0.88 (0.66, 1.19) 0.69 (0.50, 0.95) 0.51 (0.36, 0.73) <0.001 
Model 3 1 0.72 (0.54, 0.96) 0.54 (0.39, 0.73) 0.41 (0.29, 0.58) <0.001 
Model 4 1 1.00 (0.74, 1.34) 0.82 (0.59, 1.14) 0.73 (0.50, 1.05) 0.06 
Model 5 1 0.71 (0.54, 0.94) 0.52 (0.38, 0.70) 0.43 (0.30, 0.60) <0.001 
Model 6 1 0.73 (0.55, 0.96) 0.56 (0.41, 0.76) 0.49 (0.34, 0.69) <0.001 
Model 7 1 0.58 (0.44, 0.75) 0.38 (0.28, 0.50) 0.26 (0.18, 0.36) <0.001 
C24:0      
N MetS/non-MetS 260/291 160/291 90/291 55/291  
Model 1 1 0.55 (0.42, 0.71) 0.30 (0.22, 0.40) 0.19 (0.13, 0.26) <0.001 
Model 2 1 0.59 (0.44, 0.79) 0.45 (0.32, 0.62) 0.31 (0.21, 0.45) <0.001 
Model 3 1 0.50 (0.37, 0.66) 0.33 (0.24, 0.46) 0.23 (0.16, 0.33) <0.001 
Model 4 1 0.59 (0.44, 0.78) 0.43 (0.31, 0.59) 0.32 (0.22, 0.47) <0.001 
Model 5 1 0.56 (0.42, 0.74) 0.32 (0.24, 0.44) 0.23 (0.16, 0.32) <0.001 
Model 6 1 0.56 (0.42, 0.73) 0.36 (0.27, 0.50) 0.27 (0.19, 0.38) <0.001 
Model 7 1 0.51 (0.39, 0.66) 0.27 (0.20, 0.37) 0.17 (0.12, 0.24) <0.001 
Total VLCSFAsa      
N MetS/non-MetS 312/291 130/291 70/291 53/291  
Model 1 1 0.38 (0.29, 0.50) 0.21 (0.15, 0.29) 0.16 (0.11, 0.22) <0.001 
Model 2 1 0.53 (0.40, 0.71) 0.35 (0.25, 0.49) 0.30 (0.21, 0.43) <0.001 
Model 3 1 0.47 (0.35, 0.63) 0.29 (0.21, 0.40) 0.23 (0.16, 0.32) <0.001 
Model 4 1 0.58 (0.43, 0.77) 0.40 (0.28, 0.55) 0.37 (0.25, 0.53) <0.001 
Model 5 1 0.48 (0.36, 0.64) 0.29 (0.21, 0.40) 0.23 (0.16, 0.33) <0.001 
Model 6 1 0.49 (0.37, 0.65) 0.30 (0.21, 0.41) 0.25 (0.17, 0.36) <0.001 
Model 7 1 0.39 (0.30, 0.51) 0.21 (0.15, 0.29) 0.16 (0.11, 0.22) <0.001 
Logistic regression was used to estimate the ORs and CIs. VLCSFAs were classified into four group based on the quartiles of VLCSFAs in subjects without 
MetS: 0.18, 0.20 and 0.23 for C20:0; 0.59, 0.70 and 0.84 for C22:0; 0.46, 0.61 and 0.73 for C24:0; 1.32,1.51 and 1.72 for total VLCSFAs.  
Model 1: adjusted for sex, age, agricultural work, education, smoking, alcohol drinking, physical activity 
Model 2: additionally adjusted for n-6 PUFAs 
Model 3: additionally adjusted for C16:0 
Model 4: additionally adjusted for MUFAs 
Model 5: additionally adjusted for C18:0 
Model 6: additionally adjusted for C18:3n3 
Model 7: additionally adjusted for C22:6n3 
 
Supplemental Table 4. Levels of VLCSFAs according to the scores of metabolic syndrome at baseline* 
MetS scores  ≤2 3 4 5 Ptrend 
C20:0 0.21 (0.04) 0.18 (0.04) 0.18 (0.04) 0.17 (0.04) <0.0001 
C22:0 0.73 (0.20) 0.59 (0.17) 0.69 (0.22) 0.62 (0.18) <0.0001 
C24:0 0.60 (0.21) 0.58 (0.17) 0.36 (0.13) 0.36 (0.14) <0.0001 
Total VLCSFAs 1.53 (0.32) 1.35 (0.34) 1.23 (0.29) 1.15 (0.24) <0.0001 
*Levels of VLCSFAs were expressed as mean (SD) 
 
Supplemental Table 5. The associations of VLCSFAs and metabolic syndrome components 
 Quartile 1  Quartile 2 Quartile 3  Quartile 4 Ptrend 
C20:0      
N high vs low 432/ 186 229/ 163 204/ 167 141/ 208  
WC high vs low 1 0.89 (0.66, 1.20) 0.78 (0.57, 1.05) 0.47 (0.34, 0.64) <0.0001 
N high vs low 312/ 306 56/ 336 38/ 333 26/ 323  
TG high vs low 1 0.19 (0.13, 0.26) 0.11 (0.07, 0.17) 0.11 (0.07, 0.17) <0.0001 
N low vs high 196/ 422 76/ 316 81/ 290 52/ 297  
HDL low vs high 1 0.93 (0.66, 1.32) 1.22 (0.86, 1.74) 0.87 (0.58, 1.29) 0.83 
N high vs low 447/ 170 251/ 141 224/ 147 159/ 190  
BP high vs low 1 0.80 (0.60, 1.09) 0.76 (0.56, 1.03) 0.44 (0.32, 0.60) <0.0001 
N high vs low 203/ 415 95/ 297 90/ 281 79/ 270  
FBG high vs low 1 0.81 (0.60, 1.10) 0.87 (0.63, 1.19) 0.89 (0.63, 1.24) 0.47 
C22:0      
N high vs low 355/ 185 292/ 152 222/ 167 137/ 220  
WC high vs low 1 1.15 (0.85, 1.55) 0.89 (0.65, 1.21) 0.46 (0.33, 0.63) <0.0001 
N high vs low 260/ 280 95/ 349 49/ 340 28/ 329  
TG high vs low 1 0.24 (0.17, 0.32) 0.14 (0.10, 0.21) 0.10 (0.06, 0.16) <0.0001 
N low vs high 154/ 386 120/ 324 80/ 309 51/ 306  
HDL low vs high 1 1.32 (0.95, 1.83) 1.08 (0.75, 1.55) 0.86 (0.57, 1.27) 0.41 
N high vs low 379/ 386 309/ 135 234/ 155 159/ 198  
BP high vs low 1 1.07 (0.80, 1.44) 0.79 (0.58, 1.07) 0.43 (0.31, 0.58) <0.0001 
N high vs low 139/ 401 139/ 305 103/ 286 86/ 271  
FBG high vs low 1 1.61 (1.19, 2.17) 1.46 (1.05, 2.01) 1.45 (1.03, 2.05) 0.05 
C24:0      
N high vs low 332/ 219 285/ 167 229/ 152 160/ 186  
WC high vs low 1 1.21 (0.90, 1.62) 1.30 (0.95, 1.78) 0.82 (0.60, 1.13) 0.46 
N high vs low 235/ 316 136/ 316 44/ 337 17/ 329  
TG high vs low 1 0.57 (0.42, 0.77) 0.17 (0.11, 0.24) 0.07 (0.04, 0.12) <0.0001 
N low vs high 190/ 361 106/ 346 65/ 316 44/ 302  
HDL low vs high 1 0.64 (0.47, 0.88) 0.58 (0.40, 0.83) 0.55 (0.37, 0.82) 0.0004 
N high vs low 273/ 278 290/ 161 273/ 108 245/ 101  
BP high vs low 1 1.98 (1.50, 2.62) 3.21 (2.36, 4.40) 3.28 (2.38, 4.55) <0.0001 
N high vs low 142/ 409 120/ 332 93/ 288 112/ 234  
FBG high vs low 1 1.09 (0.81, 1.48) 1.09 (0.78, 1.53) 1.80 (1.29, 2.53) 0.002 
Total VLCSFAs      
N high vs low 421/ 183 238/ 183 189/ 172 158/ 186  
WC high vs low 1 0.71 (0.53, 0.96) 0.75 (0.55, 1.02) 0.55 (0.40, 0.76) 0.0004 
N high vs low 308/ 296 86/ 335 26/ 335 12/ 332  
TG high vs low 1 0.28 (0.20, 0.38) 0.09 (0.06, 0.14) 0.04 (0.02, 0.07) <0.0001 
N low vs high 214/ 390 87/ 334 53/ 308 51/ 293  
HDL low vs high 1 0.70 (0.50, 0.96) 0.60 (0.41, 0.88) 0.70 (0.47, 1.03) 0.02 
N high vs low 386/ 217 266/ 155 214/ 147 215/ 129  
BP high vs low 1 1.20 (0.90, 1.60) 1.11 (0.82, 1.52) 1.28 (0.93, 1.76) 0.17 
N high vs low 172/ 432 120/ 301 77/ 284 98/ 246  
FBG high vs low 1 1.29 (0.95, 1.74) 0.96(0.68, 1.35) 1.47 (1.05, 2.07) 0.07 
Logistic regression was used to estimate the ORs and CIs. All the ORs was adjusted for sex, age, and agricultural work. The five components were adjusted in 
the models, except for itself. The five components were classified into high/low group according to the cut-off in metabolic syndrome definition. 
BP: blood pressure, FBG: fast blood glucose, HDL: high density lipoprotein, TG: triglyceride, WC: waist circumference 



